reason report
full circl back domin hiv busi founder exit left
mp pt
bottom line last night gilead impress beat
certain extent overshadow announc
year-end departur ceo john milligan chairman
board john martin distinguish multi-decad tenur
key execut gilead announc come
surpris investor given dr milligan career gilead
rel short stint long-await ceo
posit intern successor identifi
announc clearli signal decis compani board
go differ direct dont believ
orderli departur suggest immedi issu basi
chang implic like domin investor
convers compani sever month investor
chatter like switch what gilead go buy
who gilead go hire given compani mix hire
record appointe may necessarili individu
immedi industri investor credibl certainli transit
confirm view despit obviou need signific new
pipelin product opportun gilead wont make
major strateg move potenti year
regardless surpris oper perform
quarter strong total revenu grow sequenti
beat us consensu hcv hiv result
better expect launch biktarvi show
power innov new product offer real valu gener
increment volum demand revenu base strong top-lin
result one-tim posit tax adjust report pro forma ep
beat consensu estim grew
tax windfal contribut approxim earn
surpris compar period year ago gilead revenu
ep lower sign
compani outlook least stabil level depend
durabl share gain volum growth posit mix effect
hiv busi revenu could return low singl digit growth mid-
base report result guidanc manag
commentari rais revenu forecast
later year ep estim increas
later year adjust revenu forecast
recent consensu higher
consensu pro forma ep estim gilead
averag price-to-earnings large-cap revenu
multipl slower-growth medic co
sum part exist franchis
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm non-gaap ep ex stock option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
recent consensu less
line consensu
consensu longer term gilead opportun pipelin
particularli non-alcohol steatohepat nash portfolio
jak inhibitor filgotinib seem unlik suffici
off-set sever patent expiri loom letairi
ranexa loss truvada atripla exclus us
new price gilead reiter
market perform rate gilead stock
rate gilead stock market perform price target downgrad stock
sept chang hepat market forecast compani
continu erod sharpli sooner anticip specif see
patient volum declin steadili initi peak market revenu yield per
patient continu trend neg base decreas treatment durat increas
discount manufactur compet govern commerci contract posit
forecast hcv sale declin continu eros subsequ year due
competit market dynam outlook compani hiv busi remain posit
suffici off-set unusu dynam hcv busi rel
modest contribut product offer littl mitig effect boom bust
hcv forecast total hcv revenu fall short current consensu
like drive signific neg margin trend given hcv extrem strong profit
hope gilead intern develop pipelin busi develop invest could
off-set risk opportun appear arriv late littl valu
high price gilead manag miss sever attract transact opportun
paid high premium enter oncolog market cellular therapi without declar
competit advantag gilead valuat like recov rel peer earn declin
potenti continu neg revis substanti termin uncertainti
make hard us recommend stock
total revenu beat consensu estim result
strong across board hcv come consensu
estim hiv come consensu estim even yescarta
sale exceed estim consensu gilead expand
access approxim elig patient manag indic
perform demand driven inventori stabl
hiv beat contribut market share growth prevent
care market gilead report hiv revenu includ viread/vemlidi beat
consensu estim everi individu product within portfolio
exceed consensu except descovi miss consensu gilead
manag believ revenu growth hiv continu caution us net
price stronger usual due mix payer skew toward
commerci typic privat public benefit result estim
term product mix gilead us hiv patient taf-bas
regimen european hiv patient gilead latest taf-bas medicin biktarvi
grew impress second quarter launch outpac previou
record-break genvoya launch manag disclos biktarvi prescript came
patient switch medicin one-quart genvoya one-quart dolutegravir
competit gsk product mani truvada combin one-half older gilead
hiv regimen atripla stribild mean gilead cannib major
revenu volum also stolen quarterli revenu gsk
shift older medicin equal import win market share gsk gilead must
pay double-digit royalti elvitegravir contain single-tablet regimen stribild
genvoya older regimen much shorter patent exclus biktarvi
time gilead gross margin improv materi product mix shift toward biktarvi
domin hiv product
gilead us hiv market share approach patient mix hiv
prevent segment overal number diagnos us hiv patient gilead medicin
grown sinc launch biktarvi gilead us market share
moreov gilead grown number non-infect patient prevent truvada
therapi prep yoy us patient provid ancillari growth driver
hiv top line long term above-market hiv growth sustain gilead need
continu win market share defend new product gsk also
switch prep busi truvada descovi would extend patent life
respect prevent trial descovi schedul read
import mileston compani
hcv also beat revenu declin began stabil gilead report hcv sale
beat consensu estim total hcv sale declin
sequenti lowest sequenti organ declin sinc gilead treat
patient us treat patient declin
revenu declin suggest compani price
effect lower new market price establish mp brand
combin mavyret gilead manag team anticip much gradual stabl
declin hcv sale go forward updat previou inform target
hcv sale target impli least hcv sale low end
high end
multipl one-tim item impact bottom-lin oper margin remain stabl
sequenti gilead product gross margin
consensu estim guid rang
non-gaap consensu forecast
driven undisclos payment fda prioriti review voucher like non-
sg consensu estim effect tax rate
abnorm low almost half consensu expect
driven one-tim adjust due settlement tax examin rebound
result non-gaap dilut ep recent consensu
estim
gilead maintain top-lin guidanc full-year tax rate reduc gilead maintain
previous issu top-lin financi guidanc inform hcv guidanc
non-hcv sale guidanc year gilead also continu
expect non-gaap sg expens gross margin
guidanc howev compani expect full-year tax rate
due one-tim tax settlement quarter note
impli gilead tax rate rebound
three major pipelin catalyst forthcom next month gilead manag
provid usual comprehens pipelin updat confer call believ
three major catalyst compani stock within next month first gilead
filgotinib critic first phase rheumatoid arthriti readout finch biolog
non-respond import result compani nash
program occur across two separ monotherapi phase studi selonsertib
inhibitor trial fulli enrol fibrosi patient read
respect gilead plan file simultan
two studi close togeth also gilead report prep data
descovi potenti offer life-cycl extens truvada prrp market
current us patient believ trial highli like succeed gilead
approxim year truvada patent expir switch commerci prep patient
truvada descovi
leerink revenu earn estim increas growth still look
unachiev base result quarter manag commentari
increas revenu estim long-term
forecast gilead product sale guid rang also
forecast gilead total revenu declin
begin grow increas total hcv revenu forecast
reduc long-term increas total hiv revenu
forecast long-term revenu estim
consensu
ebit margin forecast percentag point lower reflect higher
commerci spend guidanc lower gross margin percentag point higher
form due better gross margin hiv product mix heavili orient
biktarvi royalti oblig tax rate percentag point lower
rel stabl longer term result pro forma ep estim increas
ep estim recent
consensu /- base
chang revenu forecast ep estim cash flow increas
price target gilead maintain market perform rate gilead stock
price target inc base averag four approach
believ reason basi valu stock today approach trough
price earn multipl larg cap slow-growth medic product busi long term
revenu multipl larg cap medic product stock slow growth outlook sum
part valuat exist franchis discount cash flow dcf use trough consensu
forward earn multipl slow-growth medic product stock sni
gsk celg appli ep estim gilead give price
altern appli ex-growth large-cap medic product celg
revenu multipl revenu estim deriv impli valu
impli one year price target use sum part valuat exist
franchis get price consist primarili price compani hiv
franchis hcv product lastli dcf use forecast free cash flow
appli growth rate termin cash flow forecast
discount valu back present wacc give present valu
averag four approach price target
risk view outlook valuat gilead includ major chang label
price reimburs coverag compani exist hiv hcv product emerg
aggress price discount rebat valu eros hiv hcv
categori current forecast failur compani princip pipelin
asset selonsertib nash filgotinib ra ibd advanc develop
commerci opportun better perform valu expect includ
delay limit develop profil adopt competit hiv product
success develop underappreci element compani portfolio gs-
fxr agonist inhibitor follow-on car-t indic stronger-than-
expect convers current hiv patient gilead next gener taf-bas hiv treatment
royalti contract revenu
non-gaap cost good sold
share count period basic
guidanc
dilut ep impact relat acqusit
stock-bas compens
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time
follow data
nash pbc psc
leerink partner research compani report present clinicaltri gov
late stage pipelin program includ
late stage pipelin program exclud
million
darunavir/c/f-taf royalti
darunavir/c/f-taf royalti
leerink partner research compani file
million
sale incl emori amort
 total revenu
sg total revenu
profit share total revenu
leerink partner research compani file
analysi stock price leerink target
method trough price earn multipl larg cap slow growth biopharma compani
trough larg cap valu healthcar stock multipl ep sni
impli valuat ep
number period
equiti
method revenu multipl slow growth outlook larg cap biopharma stock appli
leerink revenu estim gilead
comp ex growth larg cap revenu multipl celg
impli valu gilead revenu
share outstand gilead
impli year price base revenu
method part valuat exist franchis kite
method dcf base current late stage pipelin product declin flow
wacc growth termin period
present valu late stage market product flow termin valu
net debt
present valu late stage market product flow
averag method
leerink partner research compani file factset
